A First-in-human, Open-label, Dose Escalation and Expansion Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Activity of 3HP-2827 in Patients With Unresectable or Metastatic Solid Tumors With FGFR2 Alterations
This study is testing a new experimental drug called 3HP-2827 to see if it safely helps treat solid tumors that have specific genetic changes known as FGFR2 alterations. Because this is a first-in-human trial, the main goal is to understand how the body handles the drug and if it can effectively stop or shrink these types of tumors.
This trial is for adults 18 and older whose cancer has spread or cannot be removed by surgery and has been confirmed to have the specific FGFR2 gene change. Participants must be able to perform light daily activities and meet specific health criteria regarding their heart, eyes, and overall history of other cancers.
Participants will receive the experimental drug while doctors closely monitor them for side effects and how the medication works in their system. The study happens in two stages: first to find the best dose, and then to see how well that dose works for patients.
The study is currently in the planning stage and is not yet recruiting patients. It will take place at medical centers in Phoenix, Arizona, and Houston, Texas.
- 1This is a Phase 1 study, meaning it is one of the first times this drug is being tested in humans.
- 2Participation requires regular check-ups to ensure your safety and monitor your health throughout the treatment.
- 3You will need a lab-confirmed genetic test to prove your tumor has the specific FGFR2 alteration required for this study.
No related links yet
Seen this study covered in the news, or found a page that explains it well? Send it over and we'll review it.
Suggest a linkThis summary was generated using AI and may not capture all details. Always consult with a healthcare professional for medical advice.